To find out the effect of Lu AF82422 on disease progression in participants with multiple system atrophy.
- Investigator
- Nikolaus McFarland
- Status
- Accepting Candidates
- Ages
- 40 Years - 75 Years
- Sexes
- All
Research at a glance
Top areas of exploration
- Parkinson Disease , 44 publications
- Supranuclear Palsy, Progressive , 20 publications
- Multiple System Atrophy , 15 publications
- Parkinsonian Disorders , 13 publications
Research activity
Focus
Dr. McFarland is a member of the Norman Fixel Institute for Neurological Diseases and the Center for Translational Research in Neurodegenerative Disease (CTRND), which aims to bring the bench research closer to the bedside. His research focuses on understanding the pathological mechanisms of Parkinson disease and related disorders, and on identifying novel biomarkers for early detection and tracking of disease and therapeutic development. A primary goal of his research is to identify and to develop potential novel therapeutics for Parkinson disease and related disorders. His research extends also to the clinic where he is actively involved in multiple clinical trials for atypical Parkinson disorders and Huntington disease.
Active clinical trials
This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of multiple doses of ONO-2808 in patients with MSA. This is the first study of ONO-2808 in…
- Investigator
- Nikolaus McFarland
- Status
- Accepting Candidates
- Ages
- 30 Years - 80 Years
- Sexes
- All
The Parkinson Progression Marker Initiative (PPMI) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease…
- Investigator
- Nikolaus McFarland
- Status
- Accepting Candidates
- Ages
- 30 Years - N/A
- Sexes
- All
My publications
Filter publications
104 publications
2026
Factors associated with discordant visual and quantitative amyloid PET results.
Alzheimer's & dementia (Amsterdam, Netherlands)
PubMed • Publisher's site2026
Spatial single-cell multiomics reveals peripheral immune dysfunction in Parkinson's and inflammatory bowel disease.
NPJ Parkinson's disease
PubMed • Publisher's site2026
Voice and Speech in Atypical Parkinsonian Disorders
Movement Disorders Clinical Practice
Publisher's site2025
Correction: MHCII reduction is insufficient to protect mice from alpha-synuclein-induced degeneration and the Parkinson's HLA locus exhibits epigenetic regulation.
Scientific reports
PubMed • Publisher's site2025
Cutaneous Phosphorylated Alpha-Synuclein in Lewy Body Dementia.
Annals of clinical and translational neurology
PubMed • Publisher's site